董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Alon Seri Levy | 男 | Chief Executive Officer and Director | 59 | 未披露 | 未持股 | 2021-03-04 |
| Itai Arkin | 男 | Director | 32 | 未披露 | 未持股 | 2021-03-04 |
| Shmuel Ben Zvi | 男 | Director | 60 | 未披露 | 未持股 | 2021-03-04 |
| Hani Lerman | 女 | Director | 48 | 未披露 | 未持股 | 2021-03-04 |
| Jerrold S. Gattegno | 男 | External Director | 68 | 未披露 | 未持股 | 2021-03-04 |
| Yaffa Krindel Sieradzki | 女 | Director | 66 | 未披露 | 未持股 | 2021-03-04 |
| Jonathan B. Siegel | 男 | Director | 47 | 未披露 | 未持股 | 2021-03-04 |
| Moshe Arkin | 男 | Chairman of the Board | 68 | 未披露 | 未持股 | 2021-03-04 |
| Ran Gottfried | 男 | External Director | 76 | 未披露 | 未持股 | 2021-03-04 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Gilad Mamlok | 男 | Chief Financial Officer | 52 | 未披露 | 未持股 | 2021-03-04 |
| Alon Seri Levy | 男 | Chief Executive Officer and Director | 59 | 未披露 | 未持股 | 2021-03-04 |
| Ofer Toledano | -- | Vice President Research and Development | 55 | 未披露 | 未持股 | 2021-03-04 |
| Ofra Levy Hacham | -- | Vice President Clinical and Regulatory Affairs | 54 | 未披露 | 未持股 | 2021-03-04 |
| Karine Neimann | 女 | Vice President Projects and Planning, Chief Chemist | 49 | 未披露 | 未持股 | 2021-03-04 |
| Itzik Yosef | 男 | Vice President Operations | 44 | 未披露 | 未持股 | 2021-03-04 |
| Dov Zamir | 男 | Vice President Special Projects | 67 | 未披露 | 未持股 | 2021-03-04 |
| Nissim Bilman | 男 | Vice President Quality | 59 | 未披露 | 未持股 | 2021-03-04 |
| John Vieira | 男 | U.S. Head of Commercialization | 51 | 未披露 | 未持股 | 2021-03-04 |
董事简历
中英对照 | 中文 | 英文- Alon Seri Levy
-
Alon Seri Levy联合创立了Sol-Gel，自1997年成立以来一直担任我们的首席执行官，并担任我们的董事会成员，直到2014年。在创立Sol-Gel之前，Seri-Levy博士在Peptor Ltd.（一家以色列研究与开发公司，专门从事肽类药物产品的开发）建立了计算机辅助药物设计部。Seri-Levy博士在以色列耶路撒冷希伯来大学（Hebrew University of Jerusalem）以优异成绩获得化学博士学位，并在英国牛津大学（Oxford University）进行博士后研究。Seri-Levy博士在我们的首次公开募股定价后立即被任命为我们的董事会成员。
Alon Seri Levy co-founded Sol-Gel and has served as our chief executive officer since our inception in 1997 and as a member of our board of directors until 2014. Prior to founding Sol-Gel, Dr. Seri-Levy established the computer-aided drug design department at Peptor Ltd., an Israeli research and development company that specialized in the development of peptide-based drug products. Dr. Seri-Levy holds a Ph.D. in Chemistry summa cum laude from The Hebrew University of Jerusalem, Israel, and conducted his post-doctoral studies at Oxford University, United Kingdom. Dr. Seri-Levy was appointed to our board of directors immediately following the pricing of our initial public offering. - Alon Seri Levy联合创立了Sol-Gel，自1997年成立以来一直担任我们的首席执行官，并担任我们的董事会成员，直到2014年。在创立Sol-Gel之前，Seri-Levy博士在Peptor Ltd.（一家以色列研究与开发公司，专门从事肽类药物产品的开发）建立了计算机辅助药物设计部。Seri-Levy博士在以色列耶路撒冷希伯来大学（Hebrew University of Jerusalem）以优异成绩获得化学博士学位，并在英国牛津大学（Oxford University）进行博士后研究。Seri-Levy博士在我们的首次公开募股定价后立即被任命为我们的董事会成员。
- Alon Seri Levy co-founded Sol-Gel and has served as our chief executive officer since our inception in 1997 and as a member of our board of directors until 2014. Prior to founding Sol-Gel, Dr. Seri-Levy established the computer-aided drug design department at Peptor Ltd., an Israeli research and development company that specialized in the development of peptide-based drug products. Dr. Seri-Levy holds a Ph.D. in Chemistry summa cum laude from The Hebrew University of Jerusalem, Israel, and conducted his post-doctoral studies at Oxford University, United Kingdom. Dr. Seri-Levy was appointed to our board of directors immediately following the pricing of our initial public offering.
- Itai Arkin
-
Itai Arkin在我们的首次公开募股定价后立即成为我们的董事会成员。Itai Arkin先生目前担任Arkin Holdings Ltd.的投资经理和Exalenz Bioscience Ltd.的董事会成员。Itai Arkin自2014年3月起担任以色列领先的医疗科技投资公司AccelMed和领先的梦百合对冲基金Sphera Global梦百合的投资委员会成员。Itai Arkin先生拥有以色列赫兹利亚跨学科中心工商管理学士学位和特拉维夫大学工商管理硕士学位（优等生）。Itai Arkin先生是我们董事会主席Moshe Arkin先生的儿子，也是我们控股股东Arkin Dermatology的唯一实益拥有人。
Itai Arkin became a member of our board of directors immediately following the pricing of our initial public offering. Mr. Itai Arkin currently serves as Investment Manager at Arkin Holdings Ltd. and as an investment committee member of Accelmed, a leading Israeli MedTech investment firm since March 2014. Mr. Itai Arkin holds a B.A. in business administration cum laude from Interdisciplinary Center, Herzliya, Israel, and an MBA (cum laude) from Tel Aviv University. Mr. Itai Arkin is the son of Mr. Moshe Arkin, the chairman of our board of directors and sole beneficial owner of Arkin Dermatology, our controlling shareholder. - Itai Arkin在我们的首次公开募股定价后立即成为我们的董事会成员。Itai Arkin先生目前担任Arkin Holdings Ltd.的投资经理和Exalenz Bioscience Ltd.的董事会成员。Itai Arkin自2014年3月起担任以色列领先的医疗科技投资公司AccelMed和领先的梦百合对冲基金Sphera Global梦百合的投资委员会成员。Itai Arkin先生拥有以色列赫兹利亚跨学科中心工商管理学士学位和特拉维夫大学工商管理硕士学位（优等生）。Itai Arkin先生是我们董事会主席Moshe Arkin先生的儿子，也是我们控股股东Arkin Dermatology的唯一实益拥有人。
- Itai Arkin became a member of our board of directors immediately following the pricing of our initial public offering. Mr. Itai Arkin currently serves as Investment Manager at Arkin Holdings Ltd. and as an investment committee member of Accelmed, a leading Israeli MedTech investment firm since March 2014. Mr. Itai Arkin holds a B.A. in business administration cum laude from Interdisciplinary Center, Herzliya, Israel, and an MBA (cum laude) from Tel Aviv University. Mr. Itai Arkin is the son of Mr. Moshe Arkin, the chairman of our board of directors and sole beneficial owner of Arkin Dermatology, our controlling shareholder.
- Shmuel Ben Zvi
-
Shmuel Ben Zvi在我们的首次公开募股定价后立即成为我们的董事会成员。Ben Zvi博士目前是Bank Leumi的董事会成员和审计、风险管理、技术和战略委员会成员，以及VBL Therapeutics的董事会成员和审计委员会成员。从2004年到2014年，Ben Zvi博士担任梯瓦制药工业有限公司（Teva Pharmaceuticals Industries Ltd.）的多个管理职位，包括财务Vice President和战略Vice President。从2000年到2004年，Ben Zvi博士是以色列国防军总参谋长的财务顾问和国防部预算司司长。Ben Zvi博士拥有以色列特拉维夫大学（Tel-Aviv University）经济学博士学位，并参加了哈佛商学院高级管理课程AMP。
Shmuel Ben Zvi became a member of Sol-Gel Technologies Ltd. board of directors immediately following pricing of Sol-Gel Technologies Ltd. initial public offering. Dr. Ben Zvi is currently a board member and member of the risk management, technology, investment and strategy committees at Bank Leumi, and a board member and member of the audit committee and compensation committee of VBL Therapeutics. From 2004 to 2014 Dr. Ben Zvi held various managerial positions at Teva Pharmaceuticals Industries Ltd., including Vice President of Finance and Vice President of Strategy. From 2000 to 2004 Dr. Ben Zvi was the financial advisor to the Chief of General Staff of the Israel Defense Forces and head of the Defense Ministry budget department. Dr. Ben Zvi holds a Ph.D. in economics from Tel-Aviv University, Israel and participated in the Harvard Business School Advanced Management Program AMP. - Shmuel Ben Zvi在我们的首次公开募股定价后立即成为我们的董事会成员。Ben Zvi博士目前是Bank Leumi的董事会成员和审计、风险管理、技术和战略委员会成员，以及VBL Therapeutics的董事会成员和审计委员会成员。从2004年到2014年，Ben Zvi博士担任梯瓦制药工业有限公司（Teva Pharmaceuticals Industries Ltd.）的多个管理职位，包括财务Vice President和战略Vice President。从2000年到2004年，Ben Zvi博士是以色列国防军总参谋长的财务顾问和国防部预算司司长。Ben Zvi博士拥有以色列特拉维夫大学（Tel-Aviv University）经济学博士学位，并参加了哈佛商学院高级管理课程AMP。
- Shmuel Ben Zvi became a member of Sol-Gel Technologies Ltd. board of directors immediately following pricing of Sol-Gel Technologies Ltd. initial public offering. Dr. Ben Zvi is currently a board member and member of the risk management, technology, investment and strategy committees at Bank Leumi, and a board member and member of the audit committee and compensation committee of VBL Therapeutics. From 2004 to 2014 Dr. Ben Zvi held various managerial positions at Teva Pharmaceuticals Industries Ltd., including Vice President of Finance and Vice President of Strategy. From 2000 to 2004 Dr. Ben Zvi was the financial advisor to the Chief of General Staff of the Israel Defense Forces and head of the Defense Ministry budget department. Dr. Ben Zvi holds a Ph.D. in economics from Tel-Aviv University, Israel and participated in the Harvard Business School Advanced Management Program AMP.
- Hani Lerman
-
Hani Lerman在我们的首次公开募股定价后立即成为我们的董事会成员。Lerman女士自2015年起担任Arkin Holdings首席财务官。从2010年到2014年，Lerman女士担任Sansa Security F/K/A Discretix Technologies的首席财务官，从2006年到2010年，她担任Storwize的首席财务官，该公司于2010年被IBM收购。她是Exalenz Bioscience和Sphera Global梦百合的董事会成员。她持有以色列特拉维夫大学（Tel-Aviv University）的工商管理硕士学位，主修金融，以及以色列特拉维夫大学（Tel-Aviv University，Israel）的经济学和会计学学士学位。
Hani Lerman became a member of our board of directors immediately following pricing of our initial public offering. Ms. Lerman has served as chief financial officer at Arkin Holdings since 2015. From 2010 until 2014 Ms. Lerman served as chief financial officer of Sansa Security f/k/a Discretix Technologies, and from 2006 until 2010 she served as chief financial officer of Storwize, which was acquired by IBM in 2010. She holds a Master's degree in business administration with a major in finance from Tel-Aviv University, Israel, and a B.A. in economics and accounting from Tel-Aviv University, Israel. - Hani Lerman在我们的首次公开募股定价后立即成为我们的董事会成员。Lerman女士自2015年起担任Arkin Holdings首席财务官。从2010年到2014年，Lerman女士担任Sansa Security F/K/A Discretix Technologies的首席财务官，从2006年到2010年，她担任Storwize的首席财务官，该公司于2010年被IBM收购。她是Exalenz Bioscience和Sphera Global梦百合的董事会成员。她持有以色列特拉维夫大学（Tel-Aviv University）的工商管理硕士学位，主修金融，以及以色列特拉维夫大学（Tel-Aviv University，Israel）的经济学和会计学学士学位。
- Hani Lerman became a member of our board of directors immediately following pricing of our initial public offering. Ms. Lerman has served as chief financial officer at Arkin Holdings since 2015. From 2010 until 2014 Ms. Lerman served as chief financial officer of Sansa Security f/k/a Discretix Technologies, and from 2006 until 2010 she served as chief financial officer of Storwize, which was acquired by IBM in 2010. She holds a Master's degree in business administration with a major in finance from Tel-Aviv University, Israel, and a B.A. in economics and accounting from Tel-Aviv University, Israel.
- Jerrold S. Gattegno
-
JerroldS.Gattegno在我们首次公开募股定价后立即成为我们的董事会成员，并根据《公司法》担任外部董事。他曾任职Deloitte Touche Tohmatsu Limited公司（公共会计师事务所）的纽约、华盛顿特区和伦敦办公室（1973年至2015年），在那里他曾担任多种高级职务，包括担任Deloitte&8217；s Multistate Tax Practice的主管合伙人和创始合伙人以及Deloitte&8217；s华盛顿国家税务局的管理合伙人，并担任Deloitte Tax Overseas Services LLC的董事总经理兼负责人。从2012年到2015年，Gattegno先生担任西班牙学院和大学协会的理事，并担任其财务和审计委员会的成员。Gattegno先生是一名注册会计师，在纽约城市大学（City University of New York）以优异成绩获得会计学学士学位，并在纽约佩斯大学（Pace University，New York）以优异成绩获得税务工商管理硕士学位。
Jerrold S. Gattegno became a member of our board of directors immediately following the pricing of our initial public offering and serves as an external director under the Companies Law. Mr. Gattegno worked in the New York, Washington D.C. and London offices of Deloitte Touche Tohmatsu Limited, a public accounting firm, from 1973 until 2015 where he served in various senior positions, including as the partner-in-charge and founding partner of Deloitte’s multistate tax practice and as a managing partner in Deloitte’s Washington National Tax Office, and as managing director and principal of Deloitte Tax Overseas Services LLC. Mr. Gattegno served as a governing board member of the Hispanic Association of Colleges and Universities and a member of its finance and audit committee, from 2012 until 2015. Mr. Gattegno is a certified public accountant and holds a B.S. in accounting cum laude from the City University of New York and an M.B.A. in taxation (with honors) from Pace University, New York. - JerroldS.Gattegno在我们首次公开募股定价后立即成为我们的董事会成员，并根据《公司法》担任外部董事。他曾任职Deloitte Touche Tohmatsu Limited公司（公共会计师事务所）的纽约、华盛顿特区和伦敦办公室（1973年至2015年），在那里他曾担任多种高级职务，包括担任Deloitte&8217；s Multistate Tax Practice的主管合伙人和创始合伙人以及Deloitte&8217；s华盛顿国家税务局的管理合伙人，并担任Deloitte Tax Overseas Services LLC的董事总经理兼负责人。从2012年到2015年，Gattegno先生担任西班牙学院和大学协会的理事，并担任其财务和审计委员会的成员。Gattegno先生是一名注册会计师，在纽约城市大学（City University of New York）以优异成绩获得会计学学士学位，并在纽约佩斯大学（Pace University，New York）以优异成绩获得税务工商管理硕士学位。
- Jerrold S. Gattegno became a member of our board of directors immediately following the pricing of our initial public offering and serves as an external director under the Companies Law. Mr. Gattegno worked in the New York, Washington D.C. and London offices of Deloitte Touche Tohmatsu Limited, a public accounting firm, from 1973 until 2015 where he served in various senior positions, including as the partner-in-charge and founding partner of Deloitte’s multistate tax practice and as a managing partner in Deloitte’s Washington National Tax Office, and as managing director and principal of Deloitte Tax Overseas Services LLC. Mr. Gattegno served as a governing board member of the Hispanic Association of Colleges and Universities and a member of its finance and audit committee, from 2012 until 2015. Mr. Gattegno is a certified public accountant and holds a B.S. in accounting cum laude from the City University of New York and an M.B.A. in taxation (with honors) from Pace University, New York.
- Yaffa Krindel Sieradzki
-
Yaffa Krindel Sieradzki自2016年以来一直担任我们董事会的外部董事。Krindel女士还担任Sol-gelTechnologiesLtd.的董事。纳斯达克:SLGL，一家制药公司，BGN Technologies Ltd.，Ben Gurion University的技术转让公司，以及两家医疗器械初创公司，并曾在纳斯达克公开交易的众多公司的董事会任职。从1997年到2007年，Krindel女士担任Star Ventures的合伙人兼管理合伙人，这是一家总部位于德国慕尼黑的私人风险投资基金。从1993年到1997年，Krindel女士担任Breezecom Ltd.的首席财务官，后来担任董事，该公司是一家以色列电信公司，在纳斯达克和TASE上市。1992年至1996年，Krindel女士担任Lannet Data Communications Ltd.的首席财务官兼财务副总裁，该公司是一家以色列电信公司，在纳斯达克公开交易，现为Avaya Inc.的一部分。Krindel女士还曾担任FundtechLtd.公司董事会成员，该公司在纳斯达克交易，直到被GTCR、伏尔泰有限公司收购，直到被Mellanox技术有限公司和Syneron Medical公司收购，直到被Apax公司收购。Krindel女士拥有特拉维夫大学（Tel Aviv University）的工商管理硕士学位和耶路撒冷希伯来大学（Hebrew University of Jerusalem）的经济学和日语研究学士学位。
Yaffa Krindel Sieradzki ecame a member of our board of directors on February 23 2018. Ms. Krindel-Sieradzki currently serves on the board of Itamar Medical Ltd., a medical device company publicly traded on both Nasdaq and the Tel Aviv Stock Exchange "TASE", BGN Technologies Ltd., the technology transfer company of Ben Gurion University, and three private medical device companies, as follows: EZbra Advanced Wound Care Ltd., Theranica Bio Electronics Ltd. and Trisol Medical Ltd. Ms. Krindel-Sieradzki has served on the board of directors of numerous companies publicly traded on Nasdaq. From 1997 until 2007 Ms. Krindel-Sieradzki served as Partner and Managing Partner of Star Ventures, a private venture capital fund headquartered in Munich, Germany. Before joining Star Ventures, Ms. Krindel served from 1992 to 1996 as CFO and VP Finance of Lannet Data Communications Ltd., an Israeli telecommunications company publicly traded on Nasdaq which is now part of Avaya Inc. From 1993 to 1997 she served as CFO and later as director of BreezeCOM Ltd., an Israeli telecommunications company which traded on Nasdaq and TASE. Ms. Krindel-Sieradzki has earned an M.B.A. from Tel Aviv University and a B.A. in Economics and Japanese Studies from the Hebrew University in Jerusalem, both with honors. - Yaffa Krindel Sieradzki自2016年以来一直担任我们董事会的外部董事。Krindel女士还担任Sol-gelTechnologiesLtd.的董事。纳斯达克:SLGL，一家制药公司，BGN Technologies Ltd.，Ben Gurion University的技术转让公司，以及两家医疗器械初创公司，并曾在纳斯达克公开交易的众多公司的董事会任职。从1997年到2007年，Krindel女士担任Star Ventures的合伙人兼管理合伙人，这是一家总部位于德国慕尼黑的私人风险投资基金。从1993年到1997年，Krindel女士担任Breezecom Ltd.的首席财务官，后来担任董事，该公司是一家以色列电信公司，在纳斯达克和TASE上市。1992年至1996年，Krindel女士担任Lannet Data Communications Ltd.的首席财务官兼财务副总裁，该公司是一家以色列电信公司，在纳斯达克公开交易，现为Avaya Inc.的一部分。Krindel女士还曾担任FundtechLtd.公司董事会成员，该公司在纳斯达克交易，直到被GTCR、伏尔泰有限公司收购，直到被Mellanox技术有限公司和Syneron Medical公司收购，直到被Apax公司收购。Krindel女士拥有特拉维夫大学（Tel Aviv University）的工商管理硕士学位和耶路撒冷希伯来大学（Hebrew University of Jerusalem）的经济学和日语研究学士学位。
- Yaffa Krindel Sieradzki ecame a member of our board of directors on February 23 2018. Ms. Krindel-Sieradzki currently serves on the board of Itamar Medical Ltd., a medical device company publicly traded on both Nasdaq and the Tel Aviv Stock Exchange "TASE", BGN Technologies Ltd., the technology transfer company of Ben Gurion University, and three private medical device companies, as follows: EZbra Advanced Wound Care Ltd., Theranica Bio Electronics Ltd. and Trisol Medical Ltd. Ms. Krindel-Sieradzki has served on the board of directors of numerous companies publicly traded on Nasdaq. From 1997 until 2007 Ms. Krindel-Sieradzki served as Partner and Managing Partner of Star Ventures, a private venture capital fund headquartered in Munich, Germany. Before joining Star Ventures, Ms. Krindel served from 1992 to 1996 as CFO and VP Finance of Lannet Data Communications Ltd., an Israeli telecommunications company publicly traded on Nasdaq which is now part of Avaya Inc. From 1993 to 1997 she served as CFO and later as director of BreezeCOM Ltd., an Israeli telecommunications company which traded on Nasdaq and TASE. Ms. Krindel-Sieradzki has earned an M.B.A. from Tel Aviv University and a B.A. in Economics and Japanese Studies from the Hebrew University in Jerusalem, both with honors.
- Jonathan B. Siegel
-
JonathanB.Siegel于2018年9月13日成为我们的董事会成员。Siegel先生自2017年成立以来一直担任JBS梦百合Ventures的创始人兼首席执行官。此前，他曾于2011年至2017年担任金登资本管理（Kingdon Capital Management）合伙人兼梦百合部门主管。在加入Kingdon之前，Siegel先生从2005年到2011年担任SAC Capital Advisors的梦百合投资组合经理；Stearns&Co.是Dresdner Kleinwort Wasserstein的制药研究助理，也是美国计算机科学公司生命科学部的顾问。Siegel先生曾在哈佛医学院诺华免疫生物学中心（Novartis Center for Immunobiology）担任研究助理，并在塔夫茨大学医学院（Tufts University School of Medicine）担任研究助理。他也是纳斯达克上市公司JaguarHealth，Inc.的董事，并自2019年3月起担任私人制药公司Vitalis LLC的顾问委员会成员。Siegel先生于1995年获得塔夫茨大学（Tufts University）心理学学士学位，并于1999年获得哥伦比亚商学院（Columbia Business School）工商管理硕士学位。
Jonathan B. Siegel, Opy Acquisition Corp. I chairman and chief executive officer since June 2021, is a life sciences industry veteran with more than 22 years of experience advising, investing and transacting in the healthcare sector. Mr. Siegel is the founder and chief executive officer of JBS Healthcare Ventures, a firm focused on developing cost effective solutions to improve healthcare outcomes, since its formation in 2017. Previously, he was a partner and healthcare sector head at Kingdon Capital Management, a New York City-based investment management company, from 2011 until 2017. Prior to joining Kingdon, Mr. Siegel was a healthcare portfolio manager at SAC Capital Advisors from 2005 until 2011; an associate director of pharmaceutical and specialty pharmaceutical research at Bear, Stearns & Co.; a pharmaceuticals research associate at Dresdner Kleinwort Wasserstein; and a consultant in the Life Sciences Division of Computer Sciences Corporation. Mr. Siegel has worked as a research associate at the Novartis Center for Immunobiology at Harvard Medical School where he published and presented at conferences in the field of Xenotransplantation and as a research assistant at Tufts University School of Medicine. He is also a director at Jaguar Health, Inc. since 2018 and Sol-Gel Technologies Ltd since September 2018, both Nasdaq listed companies, and has served on the board of advisors of Vitalis LLC, a private pharmaceutical company, since March 2019 and as a director of Napo Therapeutics S.p.A, the majority owned Italian subsidiary of Napo Pharmaceuticals and Jaguar Health, Inc. since 2021. Previously he served on the board of directors of Lumara Health, a private pharmaceutical company from September 2013 through October 2013 and was a board observer from November 2013 to November 2014. Mr. Siegel. Jonathan received a BS in Psychology from Tufts University in 1995 and an MBA from Columbia Business School in 1999. - JonathanB.Siegel于2018年9月13日成为我们的董事会成员。Siegel先生自2017年成立以来一直担任JBS梦百合Ventures的创始人兼首席执行官。此前，他曾于2011年至2017年担任金登资本管理（Kingdon Capital Management）合伙人兼梦百合部门主管。在加入Kingdon之前，Siegel先生从2005年到2011年担任SAC Capital Advisors的梦百合投资组合经理；Stearns&Co.是Dresdner Kleinwort Wasserstein的制药研究助理，也是美国计算机科学公司生命科学部的顾问。Siegel先生曾在哈佛医学院诺华免疫生物学中心（Novartis Center for Immunobiology）担任研究助理，并在塔夫茨大学医学院（Tufts University School of Medicine）担任研究助理。他也是纳斯达克上市公司JaguarHealth，Inc.的董事，并自2019年3月起担任私人制药公司Vitalis LLC的顾问委员会成员。Siegel先生于1995年获得塔夫茨大学（Tufts University）心理学学士学位，并于1999年获得哥伦比亚商学院（Columbia Business School）工商管理硕士学位。
- Jonathan B. Siegel, Opy Acquisition Corp. I chairman and chief executive officer since June 2021, is a life sciences industry veteran with more than 22 years of experience advising, investing and transacting in the healthcare sector. Mr. Siegel is the founder and chief executive officer of JBS Healthcare Ventures, a firm focused on developing cost effective solutions to improve healthcare outcomes, since its formation in 2017. Previously, he was a partner and healthcare sector head at Kingdon Capital Management, a New York City-based investment management company, from 2011 until 2017. Prior to joining Kingdon, Mr. Siegel was a healthcare portfolio manager at SAC Capital Advisors from 2005 until 2011; an associate director of pharmaceutical and specialty pharmaceutical research at Bear, Stearns & Co.; a pharmaceuticals research associate at Dresdner Kleinwort Wasserstein; and a consultant in the Life Sciences Division of Computer Sciences Corporation. Mr. Siegel has worked as a research associate at the Novartis Center for Immunobiology at Harvard Medical School where he published and presented at conferences in the field of Xenotransplantation and as a research assistant at Tufts University School of Medicine. He is also a director at Jaguar Health, Inc. since 2018 and Sol-Gel Technologies Ltd since September 2018, both Nasdaq listed companies, and has served on the board of advisors of Vitalis LLC, a private pharmaceutical company, since March 2019 and as a director of Napo Therapeutics S.p.A, the majority owned Italian subsidiary of Napo Pharmaceuticals and Jaguar Health, Inc. since 2021. Previously he served on the board of directors of Lumara Health, a private pharmaceutical company from September 2013 through October 2013 and was a board observer from November 2013 to November 2014. Mr. Siegel. Jonathan received a BS in Psychology from Tufts University in 1995 and an MBA from Columbia Business School in 1999.
- Moshe Arkin
-
Moshe Arkin自2014年以来一直担任我们的董事会主席。Moshe Arkin目前是几家私人制药和医疗设备公司的董事，其中包括Exalenz Bioscience Ltd.，该公司自2006年以来一直是胃肠和肝脏疾病先进系统的开发商，Sonivie Ltd.是一家开发肺动脉高压治疗系统的公司，Digma Medical，一家开发治疗2型糖尿病和其他代谢综合征疾病中存在的胰岛素抵抗的系统的公司，以及一家开发心脏瓣膜设备的公司ValCare Medical。从2005年到2008年，Moshe Arkin先生担任Perrigo Company的仿制药主管，并从2005年到2011年担任其董事会副主席。在加入我们之前，Moshe Arkin先生曾担任CCAM Biotherapeutics Ltd.的董事，该公司从2012年到2015年被默克制药公司收购，专注于发现和开发治疗癌症的新型免疫疗法从1972年Agis Industries Ltd.成立到2005年被Perrigo Company收购，Moshe Arkin先生一直担任其董事长。Moshe Arkin先生拥有以色列特拉维夫大学心理学学士学位。
Moshe Arkin has served as chairman of our board of directors since 2014. Mr. Moshe Arkin currently sits on the board of directors of several private pharmaceutical and medical device companies including Exalenz Bioscience Ltd., a developer of advanced systems for gastrointestinal and liver disorders since 2006 SoniVie Ltd., a company developing systems for the treatment of pulmonary arterial hypertension, Digma Medical, a company developing systems to treat insulin resistance present in type 2 diabetes and other metabolic syndrome diseases, and Valcare Medical, a company developing heart valve devices. From 2005 to 2008 Mr. Moshe Arkin served as the head of generics at Perrigo Company and from 2005 until 2011 as the vice chairman of its board of directors. Prior to joining us, Mr. Moshe Arkin served as a director of cCAM Biotherapeutics Ltd., a company focused on the discovery and development of novel immunotherapies to treat cancer from 2012 until its acquisition in 2015 by Merck & Co., Inc. Mr. Moshe Arkin served as chairman of Agis Industries Ltd. from its inception in 1972 until its acquisition by Perrigo Company in 2005. Mr. Moshe Arkin holds a B.A. in psychology from the Tel Aviv University, Israel. - Moshe Arkin自2014年以来一直担任我们的董事会主席。Moshe Arkin目前是几家私人制药和医疗设备公司的董事，其中包括Exalenz Bioscience Ltd.，该公司自2006年以来一直是胃肠和肝脏疾病先进系统的开发商，Sonivie Ltd.是一家开发肺动脉高压治疗系统的公司，Digma Medical，一家开发治疗2型糖尿病和其他代谢综合征疾病中存在的胰岛素抵抗的系统的公司，以及一家开发心脏瓣膜设备的公司ValCare Medical。从2005年到2008年，Moshe Arkin先生担任Perrigo Company的仿制药主管，并从2005年到2011年担任其董事会副主席。在加入我们之前，Moshe Arkin先生曾担任CCAM Biotherapeutics Ltd.的董事，该公司从2012年到2015年被默克制药公司收购，专注于发现和开发治疗癌症的新型免疫疗法从1972年Agis Industries Ltd.成立到2005年被Perrigo Company收购，Moshe Arkin先生一直担任其董事长。Moshe Arkin先生拥有以色列特拉维夫大学心理学学士学位。
- Moshe Arkin has served as chairman of our board of directors since 2014. Mr. Moshe Arkin currently sits on the board of directors of several private pharmaceutical and medical device companies including Exalenz Bioscience Ltd., a developer of advanced systems for gastrointestinal and liver disorders since 2006 SoniVie Ltd., a company developing systems for the treatment of pulmonary arterial hypertension, Digma Medical, a company developing systems to treat insulin resistance present in type 2 diabetes and other metabolic syndrome diseases, and Valcare Medical, a company developing heart valve devices. From 2005 to 2008 Mr. Moshe Arkin served as the head of generics at Perrigo Company and from 2005 until 2011 as the vice chairman of its board of directors. Prior to joining us, Mr. Moshe Arkin served as a director of cCAM Biotherapeutics Ltd., a company focused on the discovery and development of novel immunotherapies to treat cancer from 2012 until its acquisition in 2015 by Merck & Co., Inc. Mr. Moshe Arkin served as chairman of Agis Industries Ltd. from its inception in 1972 until its acquisition by Perrigo Company in 2005. Mr. Moshe Arkin holds a B.A. in psychology from the Tel Aviv University, Israel.
- Ran Gottfried
-
Ran Gottfried，2006年2月以来，一直担任Perrigo的董事。2006年至2008年12月，他担任Powerpaper Ltd.的董事长、首席执行官，这是微电化妆品和药物贴片的顶尖开发制造商。1975年以来，他在以色列和欧洲的多个私营企业担任过首席执行官、顾问、董事，涉及零售与分销、制药、电信等领域。2001-2005，他担任Magnolia Silver Jewelry, Ltd.的董事长。2004-2007，他还曾担任Careline-Neca的顾问，这是Perrigo以色列子公司的消费品部门。2003年起，他担任Agis的董事，直到2005年它被Perrigo收购；2005年至2010年4月，担任Bezeq的董事，这是以色列顶尖的电信提供商。他目前居住在以色列。
Ran Gottfried became a member of our board of directors immediately following the pricing of our initial public offering and serves as an external director under the Companies Law. Since 1975 Mr. Gottfried has served as a chief executive officer, consultant and director of private companies in Israel and Europe in the areas of retail and distribution of pharmaceuticals, consumer and household products. Mr. Gottfried served as a director of Perrigo Company from 2006 until 2015. From 2006 until 2008 Mr. Gottfried served as chairman and chief executive officer of Powerpaper Ltd., a leading developer and manufacturer of micro electrical cosmetic and pharmaceutical patches. From 2005 until 2010 Mr. Gottfried served as a director of Bezeq, Israel’s leading telecommunications provider and from 2003 until its acquisition by Perrigo Company in 2005 Mr. Gottfried served as a director of Agis Industries Ltd. He is currently a board member and member of the audit and investment, technology and innovation and risk management committees at Shufersal Ltd. - Ran Gottfried，2006年2月以来，一直担任Perrigo的董事。2006年至2008年12月，他担任Powerpaper Ltd.的董事长、首席执行官，这是微电化妆品和药物贴片的顶尖开发制造商。1975年以来，他在以色列和欧洲的多个私营企业担任过首席执行官、顾问、董事，涉及零售与分销、制药、电信等领域。2001-2005，他担任Magnolia Silver Jewelry, Ltd.的董事长。2004-2007，他还曾担任Careline-Neca的顾问，这是Perrigo以色列子公司的消费品部门。2003年起，他担任Agis的董事，直到2005年它被Perrigo收购；2005年至2010年4月，担任Bezeq的董事，这是以色列顶尖的电信提供商。他目前居住在以色列。
- Ran Gottfried became a member of our board of directors immediately following the pricing of our initial public offering and serves as an external director under the Companies Law. Since 1975 Mr. Gottfried has served as a chief executive officer, consultant and director of private companies in Israel and Europe in the areas of retail and distribution of pharmaceuticals, consumer and household products. Mr. Gottfried served as a director of Perrigo Company from 2006 until 2015. From 2006 until 2008 Mr. Gottfried served as chairman and chief executive officer of Powerpaper Ltd., a leading developer and manufacturer of micro electrical cosmetic and pharmaceutical patches. From 2005 until 2010 Mr. Gottfried served as a director of Bezeq, Israel’s leading telecommunications provider and from 2003 until its acquisition by Perrigo Company in 2005 Mr. Gottfried served as a director of Agis Industries Ltd. He is currently a board member and member of the audit and investment, technology and innovation and risk management committees at Shufersal Ltd.
高管简历
中英对照 | 中文 | 英文- Gilad Mamlok
Gilad Mamlok，2015年8月以来，他担任我们首席财务官。从2014年到2015年，他担任Covidien plc的副总裁金融。从2005年到2014年，他担任Given Imaging Ltd.的全球金融和会计高级副总裁。从2004年到2005年，他担任Metacure Israel Ltd.（医疗器械公司）首席财务官。从2002年到2004年，他担任 Simbionix USA Corporation首席财务官。从1997年到2002年，他担任NICE Systems Ltd.的财务总监。他持有特拉维夫大学（Tel-Aviv University）经济学学士和硕士学位以及美国the University of Rochester经济学博士学Lone Star Bank位。
Gilad Mamlok has served as our chief financial officer since February 2017. From August 2015 to January 2017 Mr. Mamlok served as the chief financial officer for Medigus Ltd., a medical device company dual listed on Nasdaq and the Tel Aviv Stock Exchange, or the TASE. From September 2005 to March 2015 Mr. Mamlok served as senior vice president, global finance and accounting of Given Imaging Ltd., a medical device company dual listed on Nasdaq and TASE, acquired by Covidien plc in February 2014. From January 2002 to September 2005 Mr. Mamlok served as chief financial officer of two other medical device companies. Mr. Mamlok holds a Master's degree in business economics from Tel-Aviv University and a B.A. in economics magna cum laude from Tel-Aviv University, Israel.- Gilad Mamlok，2015年8月以来，他担任我们首席财务官。从2014年到2015年，他担任Covidien plc的副总裁金融。从2005年到2014年，他担任Given Imaging Ltd.的全球金融和会计高级副总裁。从2004年到2005年，他担任Metacure Israel Ltd.（医疗器械公司）首席财务官。从2002年到2004年，他担任 Simbionix USA Corporation首席财务官。从1997年到2002年，他担任NICE Systems Ltd.的财务总监。他持有特拉维夫大学（Tel-Aviv University）经济学学士和硕士学位以及美国the University of Rochester经济学博士学Lone Star Bank位。
- Gilad Mamlok has served as our chief financial officer since February 2017. From August 2015 to January 2017 Mr. Mamlok served as the chief financial officer for Medigus Ltd., a medical device company dual listed on Nasdaq and the Tel Aviv Stock Exchange, or the TASE. From September 2005 to March 2015 Mr. Mamlok served as senior vice president, global finance and accounting of Given Imaging Ltd., a medical device company dual listed on Nasdaq and TASE, acquired by Covidien plc in February 2014. From January 2002 to September 2005 Mr. Mamlok served as chief financial officer of two other medical device companies. Mr. Mamlok holds a Master's degree in business economics from Tel-Aviv University and a B.A. in economics magna cum laude from Tel-Aviv University, Israel.
- Alon Seri Levy
Alon Seri Levy联合创立了Sol-Gel，自1997年成立以来一直担任我们的首席执行官，并担任我们的董事会成员，直到2014年。在创立Sol-Gel之前，Seri-Levy博士在Peptor Ltd.（一家以色列研究与开发公司，专门从事肽类药物产品的开发）建立了计算机辅助药物设计部。Seri-Levy博士在以色列耶路撒冷希伯来大学（Hebrew University of Jerusalem）以优异成绩获得化学博士学位，并在英国牛津大学（Oxford University）进行博士后研究。Seri-Levy博士在我们的首次公开募股定价后立即被任命为我们的董事会成员。
Alon Seri Levy co-founded Sol-Gel and has served as our chief executive officer since our inception in 1997 and as a member of our board of directors until 2014. Prior to founding Sol-Gel, Dr. Seri-Levy established the computer-aided drug design department at Peptor Ltd., an Israeli research and development company that specialized in the development of peptide-based drug products. Dr. Seri-Levy holds a Ph.D. in Chemistry summa cum laude from The Hebrew University of Jerusalem, Israel, and conducted his post-doctoral studies at Oxford University, United Kingdom. Dr. Seri-Levy was appointed to our board of directors immediately following the pricing of our initial public offering.- Alon Seri Levy联合创立了Sol-Gel，自1997年成立以来一直担任我们的首席执行官，并担任我们的董事会成员，直到2014年。在创立Sol-Gel之前，Seri-Levy博士在Peptor Ltd.（一家以色列研究与开发公司，专门从事肽类药物产品的开发）建立了计算机辅助药物设计部。Seri-Levy博士在以色列耶路撒冷希伯来大学（Hebrew University of Jerusalem）以优异成绩获得化学博士学位，并在英国牛津大学（Oxford University）进行博士后研究。Seri-Levy博士在我们的首次公开募股定价后立即被任命为我们的董事会成员。
- Alon Seri Levy co-founded Sol-Gel and has served as our chief executive officer since our inception in 1997 and as a member of our board of directors until 2014. Prior to founding Sol-Gel, Dr. Seri-Levy established the computer-aided drug design department at Peptor Ltd., an Israeli research and development company that specialized in the development of peptide-based drug products. Dr. Seri-Levy holds a Ph.D. in Chemistry summa cum laude from The Hebrew University of Jerusalem, Israel, and conducted his post-doctoral studies at Oxford University, United Kingdom. Dr. Seri-Levy was appointed to our board of directors immediately following the pricing of our initial public offering.
- Ofer Toledano
自2004年以来，Ofer Toledano一直是我们研究与开发的Vice President。加入Sol-Gel公司之前，Toledano博士从1998年到2004年担任Adama Agricultural SolutionsLtd.（原名Makhteshim Agan Industries Ltd.）的配方部经理，该公司是一家以色列作物保护产品制造商和分销商。Toledano博士拥有以色列耶路撒冷希伯来大学（Hebrew University of Jerusalem，Israel）化学博士学位。
Ofer Toledano has served as our vice president of research and development since 2004. Prior to joining Sol-Gel, Dr. Toledano served as manager of the formulation department at ADAMA Agricultural Solutions Ltd. formerly known as Makhteshim Agan Industries Ltd., an Israeli manufacturer and distributor of crop protection products from 1998 until 2004. Dr. Toledano holds a Ph.D. in chemistry from The Hebrew University of Jerusalem, Israel.- 自2004年以来，Ofer Toledano一直是我们研究与开发的Vice President。加入Sol-Gel公司之前，Toledano博士从1998年到2004年担任Adama Agricultural SolutionsLtd.（原名Makhteshim Agan Industries Ltd.）的配方部经理，该公司是一家以色列作物保护产品制造商和分销商。Toledano博士拥有以色列耶路撒冷希伯来大学（Hebrew University of Jerusalem，Israel）化学博士学位。
- Ofer Toledano has served as our vice president of research and development since 2004. Prior to joining Sol-Gel, Dr. Toledano served as manager of the formulation department at ADAMA Agricultural Solutions Ltd. formerly known as Makhteshim Agan Industries Ltd., an Israeli manufacturer and distributor of crop protection products from 1998 until 2004. Dr. Toledano holds a Ph.D. in chemistry from The Hebrew University of Jerusalem, Israel.
- Ofra Levy Hacham
Ofra Levy Hacham自2018年以来一直担任我们的临床保证和监管事务Vice President，并于2011年至2018年担任我们的质量和监管事务Vice President。加入Sol-Gel之前，Levy-Hacham从2010年到2011年担任Biotechnology General Ltd.（Ferring Pharmaceuticals Ltd.的全资子公司，一家完全集成的生物制药服务私人公司）科学专家和项目经理。从2005年到2010年，Levy-Hacham博士担任Healor Ltd.的化学、制造和控制Vice President，该公司是一家私人公司，从事治疗各种皮肤病的疗法的开发。Levy-Hacham博士拥有以色列Technion-Israel Institute of Technology的化学博士学位。
Ofra Levy Hacham has served as our vice president of clinical and regulatory affairs since 2018 and as our vice president of quality and regulatory affairs from 2011 to 2018. Prior to joining Sol-Gel, Dr. Levy-Hacham served as a scientific specialist and project manager at Biotechnology General Ltd., a wholly owned subsidiary of Ferring Pharmaceuticals Ltd., and a fully integrated biopharmaceutical services private company from 2010 until 2011. From 2005 until 2010 Dr. Levy-Hacham served as vice president chemistry, manufacturing and controls at HealOr Ltd., a private company engaging in the development of therapeutics for the treatment of various skin disorders. Dr. Levy-Hacham holds a Ph.D. in chemistry from The Technion - Israel Institute of Technology, Israel.- Ofra Levy Hacham自2018年以来一直担任我们的临床保证和监管事务Vice President，并于2011年至2018年担任我们的质量和监管事务Vice President。加入Sol-Gel之前，Levy-Hacham从2010年到2011年担任Biotechnology General Ltd.（Ferring Pharmaceuticals Ltd.的全资子公司，一家完全集成的生物制药服务私人公司）科学专家和项目经理。从2005年到2010年，Levy-Hacham博士担任Healor Ltd.的化学、制造和控制Vice President，该公司是一家私人公司，从事治疗各种皮肤病的疗法的开发。Levy-Hacham博士拥有以色列Technion-Israel Institute of Technology的化学博士学位。
- Ofra Levy Hacham has served as our vice president of clinical and regulatory affairs since 2018 and as our vice president of quality and regulatory affairs from 2011 to 2018. Prior to joining Sol-Gel, Dr. Levy-Hacham served as a scientific specialist and project manager at Biotechnology General Ltd., a wholly owned subsidiary of Ferring Pharmaceuticals Ltd., and a fully integrated biopharmaceutical services private company from 2010 until 2011. From 2005 until 2010 Dr. Levy-Hacham served as vice president chemistry, manufacturing and controls at HealOr Ltd., a private company engaging in the development of therapeutics for the treatment of various skin disorders. Dr. Levy-Hacham holds a Ph.D. in chemistry from The Technion - Israel Institute of Technology, Israel.
- Karine Neimann
Karine Neimann自2016年9月起担任我们的项目和计划Vice President兼首席化学家。自2008年加入我们以来，Neimann博士担任过各种职务，包括首席化学家和实验室经理。Neimann博士拥有以色列耶路撒冷希伯来大学（Hebrew University of Jerusalem，Israel）化学博士学位。
Karine Neimann has served as our vice president of projects and planning and chief chemist since September 2016. Since joining us in 2008 Dr. Neimann held various positions, including as chief chemist and laboratory manager. Dr. Neimann holds a Ph.D. in chemistry from The Hebrew University of Jerusalem, Israel.- Karine Neimann自2016年9月起担任我们的项目和计划Vice President兼首席化学家。自2008年加入我们以来，Neimann博士担任过各种职务，包括首席化学家和实验室经理。Neimann博士拥有以色列耶路撒冷希伯来大学（Hebrew University of Jerusalem，Israel）化学博士学位。
- Karine Neimann has served as our vice president of projects and planning and chief chemist since September 2016. Since joining us in 2008 Dr. Neimann held various positions, including as chief chemist and laboratory manager. Dr. Neimann holds a Ph.D. in chemistry from The Hebrew University of Jerusalem, Israel.
- Itzik Yosef
Itzik Yosef自2016年8月起担任我们的运营Vice President。自2010年加入公司以来，Yosef博士担任多个职位，包括运营主管。Yosef博士拥有以色列耶路撒冷希伯来大学（Hebrew University of Jerusalem，Israel）化学博士学位。
Itzik Yosef has served as our vice president of operations since August 2016. Since joining us in 2010 Dr. Yosef held various positions including as head of operations. Dr. Yosef holds a Ph.D. in chemistry from The Hebrew University of Jerusalem, Israel.- Itzik Yosef自2016年8月起担任我们的运营Vice President。自2010年加入公司以来，Yosef博士担任多个职位，包括运营主管。Yosef博士拥有以色列耶路撒冷希伯来大学（Hebrew University of Jerusalem，Israel）化学博士学位。
- Itzik Yosef has served as our vice president of operations since August 2016. Since joining us in 2010 Dr. Yosef held various positions including as head of operations. Dr. Yosef holds a Ph.D. in chemistry from The Hebrew University of Jerusalem, Israel.
- Dov Zamir
Dov Zamir自2016年8月以来一直担任我们的Vice President特别项目。在加入我们之前，Zamir博士于2007年至2016年领导CIMA Nanotech Ltd.（一家私营公司，开发基于先进纳米技术的涂层配方）的研发小组。从2004年到2007年，他曾担任Taro Pharmaceutical Industries公司（位于海法）的制药和分析研发副总裁，此前曾管理其分析研发实验室3年。Zamir博士拥有以色列特拉维夫大学（Tel-Aviv University）的有机化学博士学位。
Dov Zamir has served as our vice president special projects since August 2016. Prior to joining us, Dr. Zamir lead the R&D group in Cima NanoTech Ltd., a private company developing sophisticated nanotechnology-based coating formulations from 2007 until 2016. From 2004 to 2007 Dr. Zamir was VP of Pharma and Analytical R&D at Taro Pharmaceutical Industries in Haifa, and for three years prior to that he managed its Analytical R&D lab. Dr. Zamir holds a Ph.D. in organic chemistry from Tel-Aviv University, Israel.- Dov Zamir自2016年8月以来一直担任我们的Vice President特别项目。在加入我们之前，Zamir博士于2007年至2016年领导CIMA Nanotech Ltd.（一家私营公司，开发基于先进纳米技术的涂层配方）的研发小组。从2004年到2007年，他曾担任Taro Pharmaceutical Industries公司（位于海法）的制药和分析研发副总裁，此前曾管理其分析研发实验室3年。Zamir博士拥有以色列特拉维夫大学（Tel-Aviv University）的有机化学博士学位。
- Dov Zamir has served as our vice president special projects since August 2016. Prior to joining us, Dr. Zamir lead the R&D group in Cima NanoTech Ltd., a private company developing sophisticated nanotechnology-based coating formulations from 2007 until 2016. From 2004 to 2007 Dr. Zamir was VP of Pharma and Analytical R&D at Taro Pharmaceutical Industries in Haifa, and for three years prior to that he managed its Analytical R&D lab. Dr. Zamir holds a Ph.D. in organic chemistry from Tel-Aviv University, Israel.
- Nissim Bilman
Nissim Bilman于2018年8月15日成为溶胶凝胶的Vice President质量。从2004年到2018年，Bilman先生担任QPRO Pharma（一家项目管理和咨询公司，提供与制药行业相关的服务）的首席执行官。从2011年到2018年，他担任Exalenz Bioscience的Vice President药物开发。Bilman从2007年到2010年担任Gelesis Inc./Gelesis R&D Ltd.研发和制造副总裁以及现场经理。Bilman先生拥有以色列希伯来大学（Hebrew University）的化学和气象学学士学位，以及应用化学理学硕士学位。
Nissim Bilman became Vice President Quality of Sol-Gel on the August 15 2018. From 2004 until 2018 Mr. Bilman served as CEO of QPRO Pharma, a project management and consulting company offering services related to the pharmaceutical industry. From 2011 until 2018 he served as the Vice President Drug Development of Exalenz Bioscience. From 2007 until 2010 Mr. Bilman served as VP R&D and Manufacturing and Site Manager for Gelesis Inc./Gelesis R&D Ltd. Mr. Bilman holds a Bachelor Degree in Chemistry and Meteorology, as well as a Master of Science in Applied Chemistry, both from the Hebrew University in Israel.- Nissim Bilman于2018年8月15日成为溶胶凝胶的Vice President质量。从2004年到2018年，Bilman先生担任QPRO Pharma（一家项目管理和咨询公司，提供与制药行业相关的服务）的首席执行官。从2011年到2018年，他担任Exalenz Bioscience的Vice President药物开发。Bilman从2007年到2010年担任Gelesis Inc./Gelesis R&D Ltd.研发和制造副总裁以及现场经理。Bilman先生拥有以色列希伯来大学（Hebrew University）的化学和气象学学士学位，以及应用化学理学硕士学位。
- Nissim Bilman became Vice President Quality of Sol-Gel on the August 15 2018. From 2004 until 2018 Mr. Bilman served as CEO of QPRO Pharma, a project management and consulting company offering services related to the pharmaceutical industry. From 2011 until 2018 he served as the Vice President Drug Development of Exalenz Bioscience. From 2007 until 2010 Mr. Bilman served as VP R&D and Manufacturing and Site Manager for Gelesis Inc./Gelesis R&D Ltd. Mr. Bilman holds a Bachelor Degree in Chemistry and Meteorology, as well as a Master of Science in Applied Chemistry, both from the Hebrew University in Israel.
- John Vieira
John Vieira自2019年1月起担任我们的美国商业化负责人。在加入Sol-Gel之前，Vieira先生曾在利欧股份Pharmaceuticals担任美国和全球营销职务。在加入利欧股份制药公司之前，Vieira先生是Daiichi Sankyo血栓形成公司的执行董事，在那里他领导了一种主要抗凝剂的全球发布，此前他在美国商业运营中担任过多个高级领导职务。在加入Daiichi Sankyo之前，Vieira先生曾在几家梦百合公司担任领导职务，包括Organon Biopharmaceuticals公司和葛兰素史克公司，在不同的治疗领域成功地推出了六种以上的全球和美国新产品。Vieira先生拥有罗格斯大学（Rutgers University）的工商管理硕士学位和加拿大多伦多约克大学（York University）的工商管理学士学位。
John Vieira has served as our U.S. head of commercialization since January 2019. Prior to joining Sol-Gel, Mr. Vieira served in U.S. and Global Marketing roles at Leo Pharmaceuticals. Prior to Leo Pharmaceuticals, Mr. Vieira was Executive Director, Thrombosis, at Daiichi Sankyo, where he led the global launch of a major anti-coagulant, following various senior leadership roles in the U.S. commercial operations. Prior to Daiichi Sankyo, Mr. Vieira held leadership positions at several healthcare companies, including Organon Biopharmaceuticals and GlaxoSmithKline, successfully launching over six new global and U.S. products in diverse therapeutic areas. Mr. Vieira holds an M.B.A. degree from Rutgers University and a B.A. degree from York University in Toronto, Canada.- John Vieira自2019年1月起担任我们的美国商业化负责人。在加入Sol-Gel之前，Vieira先生曾在利欧股份Pharmaceuticals担任美国和全球营销职务。在加入利欧股份制药公司之前，Vieira先生是Daiichi Sankyo血栓形成公司的执行董事，在那里他领导了一种主要抗凝剂的全球发布，此前他在美国商业运营中担任过多个高级领导职务。在加入Daiichi Sankyo之前，Vieira先生曾在几家梦百合公司担任领导职务，包括Organon Biopharmaceuticals公司和葛兰素史克公司，在不同的治疗领域成功地推出了六种以上的全球和美国新产品。Vieira先生拥有罗格斯大学（Rutgers University）的工商管理硕士学位和加拿大多伦多约克大学（York University）的工商管理学士学位。
- John Vieira has served as our U.S. head of commercialization since January 2019. Prior to joining Sol-Gel, Mr. Vieira served in U.S. and Global Marketing roles at Leo Pharmaceuticals. Prior to Leo Pharmaceuticals, Mr. Vieira was Executive Director, Thrombosis, at Daiichi Sankyo, where he led the global launch of a major anti-coagulant, following various senior leadership roles in the U.S. commercial operations. Prior to Daiichi Sankyo, Mr. Vieira held leadership positions at several healthcare companies, including Organon Biopharmaceuticals and GlaxoSmithKline, successfully launching over six new global and U.S. products in diverse therapeutic areas. Mr. Vieira holds an M.B.A. degree from Rutgers University and a B.A. degree from York University in Toronto, Canada.